International Stereotactic Radiosurgery Society

Become a member | Log In | Contact us

The ISRS webinar series began in 2016. We have already delivered over 50 webinars on intracranial and body SRS and from experts around around the world.

A video replay of each past webinar is available to ISRS members.

Next Webinars

April 25, 2019

Stereotactic Radiotherapy and Radiosurgery for Neurosurgical Pathology in Pediatric Patients by Andrey GOLANOV, MD, PhD

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00pm (Brisbane)

The presentation will be devoted to the experience of treatment (more than 1,500 observations) of pediatric patients with various tumors (benign and malignant gliomas, craniopharyngiomas, medulloblastomas, etc.) and vascular pathology in the radiotherapy and radiosurgery department and in the center of Gamma Knife (Moscow, Russia). Indications, peculiarities of carrying out, long-term results of application will be given and the possibilities of stereotactic irradiation in the children's neurosurgical clinic will be discussed.

May 07, 2019

How Small is Too Small? QA & QC for HyperArcTM SRS by Richard POPPLE, PhD, Professor and Vice-Chair for Physics

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00pm (Brisbane)

Quality assurance for linear accelerator intracranial radiosurgery using the Varian HyperArcTMsystem will be discussed. Both mechanical and dosimetric QA will be reviewed, with particular emphasis on patient-specific dosimetry of targets as small as 3 mm. The experience at The University of Alabama at Birmingham will be presented.

May 23, 2019

Stereotactic Radiotherapy for Oligometastatic Cancer: Expanding Reality by Barbara Alicja JERECZEK-FOSSA, MD, PhD, Associate Professor

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00pm (Brisbane)

The incidence of oligometastatic cancer (low burden metastatic disease) is constantly growing due to the advancement in medical imaging and increase in primary cancer cure rates. Metastasectomy and other local modalities including stereotactic radiotherapy, termoablation, high intensity focus ultrasound (HIFU) etc. have been introduced in this particular clinical scenario. New terms like metastasis-directed therapy (MDT) and local or lesion ablative treatment (LAT) have been coined and help to distinguish the radical local strategies from palliative local therapies (palliative treatment). Stereotactic radiotherapy is now frequently proposed in oligometastatic cancer patient and provides high local control and, in some cases, long lasting progression-free and treatment-free intervals. 

June 03, 2019

SRS for Large Intracranial AVMs by Kita SALLABANDA, MD, Professor

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00pm (Brisbane)

July 11, 2019

When is SABR the Preferred Treatment in Lung Cancer? by Ben SLOTMAN, MD, PhD, Associate Professor

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00 pm (Brisbane)

The clinical use of SABR for early stage non-small cell lung cancer has increased considerable during the last decade. In this webinar, current and future indication for SABR in this disease will be discussed. Treatment of patients with a higher risk of toxicity due to tumor location or presence of interstitial lung disease will be addressed as well.